Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    17341662 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Combination Chemotherapy Plus PSC 833 Followed by Interleukin-2 in Treating Patients With Acute Myelogenous Leukemia
Condition: Leukemia
Interventions: Drug: ara-C;   Drug: Daunorubicin;   Drug: Etoposide;   Drug: PSC-833;   Biological: Aldesleukin

Indicates status has not been verified in more than two years